Allogene Therapeutics logo

Allogene Therapeutics

ALLO | NASDAQ
Chart Builder DCF Calculator
$0.81
-$0.03 (-3.42%)
At close: Nov 16, 2026, 4:00 PM ET
$0.81
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-3.42%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 14, 2026
52.5
Fundamentals Strong
Market Sentiment Neutral
Moat None
Sector Rank #221/1021 (Top 22%)

Key Statistics

Market Data

Market Cap $279.6M
1D Range
0.77 0.85
52W Range
0.77 3.06

Valuation (TTM)

PE -1.29
PB 0.71
EV/EBITDA -0.32

Valuation (NTM)

Forward PE N/A
Forward PEG 0.04
Price Target $6.43
Loading financial charts...

Profile

Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of...

Sector Healthcare
Industry Biotechnology
Employees 151
IPO Date Oct 11, 2018
Fiscal Year January - December

Latest News

No news articles available yet.

Earnings

Next Earnings
Mar 11, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
9
Consensus
Buy
Price Target
$6.43
Upside
+693.83%
Buy (6)
Hold (3)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.